(Q34384415)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

adaptive radiation therapy

11 November 2019

main subject

0 references

author

Michael Baumann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Daniel Zips

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

S Appold

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

C Petersen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

T Herrmann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 September 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

33 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

S35-45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Medically Inoperable Lung Carcinoma: The Role of Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Three-Dimensional Conformal Radiation Therapy In Bronchogenic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

The impact of three-dimensional radiation on the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Hyperfractionated radiotherapy: tops or flops?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Quantitative clinical radiobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Accelerated fractionation vs hyperfractionation: rationales for several treatments per day.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Biologic basis for altered fractionation schemes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Quantitative clinical radiobiology of early and late lung reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Linear-quadratic analysis of tumour response to fractionated radiotherapy: a study on human squamous cell carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Hyperfractionation: where do we stand?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

[What do we know about the mechanisms of the time factor in oncological therapy?]

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Three A's of repopulation during fractionated irradiation of squamous epithelia: Asymmetry loss, Acceleration of stem-cell divisions and Abortive divisions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

[CHARTWEL-Bronchus (ARO 97-1): a randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperable non-small-call bronchial carcinoma]

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

[Results of irradiation of inoperable stage III non-small cell lung cancer with 25Gy in five fractions]

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Wor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Predictive factors in radiotherapy for non-small cell lung cancer: present status.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Novel approaches to locally advanced unresectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Effect of irradiated volume on lung damage in pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Damage and morbidity from pneumonitis after irradiation of partial volumes of mouse lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Quantification of radiation-induced regional lung injury with perfusion imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Dose-effect relations for early local pulmonary injury after irradiation for malignant lymphoma and breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Lack of effect of small high-dose volumes on the dose-response relationship for the development of fibrosis in distant parts of the ipsilateral lung in mini-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Target volume definition for three-dimensional conformal radiation therapy of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Point: the potential importance of elective nodal irradiation in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

Counterpoint: better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900301-4

7 January 2021

10.1016/S0169-5002(01)00301-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11576706%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference